Biological Analysis of MABs in NHL in a Translational Prospective Observational Study Within Italian Clinical Practice

This a prospective, multicenter, observational pharmacological translational study designed to investigate the biological and imaging correlates of treatment with novel monoclonal antibodies (NMABs) in patients with B-cell non-Hodgkin lymphoma (NHL), enrolled in the observational FIL\_MAB study. All clinical observations, including baseline characteristics, treatment exposure, and follow-up, are collected through the FIL-MAB study database, with a minimum follow-up of 60 months (5 years) from enrollment and correlated with biological findings for translational analysis performed in BIO-FIL\_MAB study. The BIO-FIL\_MAB study will employ a structured schedule of biological and imaging assessments to monitor treatment outcomes and gather translational data. The timeline will be aligned with routine clinical practice: * Prior to NMAB Treatment * During NMAB Therapy (3 months after start of therapy, 9 months after start of therapy, progression/relapse). This structured schedule ensures a comprehensive evaluation of both clinical and biological treatment effects, aligning with the study's translational objectives. As an observational translational study primarily intended for descriptive and exploratory analyses, no formal statistical hypothesis testing is planned. Therefore, the sample size has been determined based on feasibility considerations and the expected availability of patients participating in the parent FIL-MAB clinical cohort, thereby ensuring a robust population for integrated biological, immunological, and imaging analyses in association with clinical outcomes. Overall, it is anticipated that at least 1000 patients will be consecutively enrolled and followed longitudinally in BIO-FIL\_MAB study.